ArticleAdvanced pharmaceutical bulletin2020
Angiotensin 1-7: A Novel Strategy in COVID-19 Treatment.
Article in Advanced pharmaceutical bulletin, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Comparison of losartan and amlodipine effects on the outcomes of patient with COVID-19 and primary hypertension: A randomised clinical trial.International journal of clinical practice · 2021Trial
- N-acetylcysteine as adjuvant therapy for hospitalized Covid-19 patients: A single-center prospective cohort study.Caspian journal of internal medicine · 2023Article
- Low Ang-(1-7) and high des-Arg9 bradykinin serum levels are correlated with cardiovascular risk factors in patients with COVID-19.Open medicine (Warsaw, Poland) · 2023Article
- Unveiling the G4-PAMAM capacity to bind and protect Ang-(1-7) bioactive peptide by molecular dynamics simulations.Journal of computer-aided molecular design · 2022Article
- Covid-19 and oral diseases: Crosstalk, synergy or association?Reviews in medical virology · 2021Review
- The fight against COVID-19: Striking a balance in the renin-angiotensin system.Drug discovery today · 2021Review
- Drug-drug interactions with candidate medications used for COVID-19 treatment: An overview.Pharmacology research & perspectives · 2021Review
- Concurrent chronic lymphocytic leukemia and COVID-19: A comprehensive review of epidemiological, diagnostic, and therapeutic challenges.Leukemia research reports · 2021Review
- Dyspneic and non-dyspneic (silent) hypoxemia in COVID-19: Possible neurological mechanism.Clinical neurology and neurosurgery · 2020Review
- Molecular and Biological Mechanisms Underlying Gender Differences in COVID-19 Severity and Mortality.Frontiers in immunologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.